Nusinersen - Biogen/Ionis Pharmaceuticals
Alternative Names: BIIB-058; IONIS-SMNRx; ISIS-396443; ISIS-SMNRx; SpinrazaLatest Information Update: 28 Nov 2025
At a glance
- Originator Cold Spring Harbor Laboratory; Isis Pharmaceuticals
- Developer Biogen; Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action RNA interference; Survival of motor neuron 2 protein expression stimulants
-
Orphan Drug Status
Yes - Spinal muscular atrophy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Spinal muscular atrophy
Most Recent Events
- 17 Nov 2025 Nusinersen receives positive CHMP opinion from the European Medicines Agency for 5q Spinal muscular atrophy
- 03 Nov 2025 Preregistration for Spinal muscular atrophy (In adolescents, Treatment-experienced, In adults) in USA (Intrathecal)
- 30 Oct 2025 FDA assigns PDUFA action date of 03/04/2026 for Nusinersen for Spinal muscular atrophy